Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.49 |
| ▸ | GLP1R | P43220 | 1/20 | 0.48 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | RET | P07949 | 2/20 | 0.43 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.42 |
| ▸ | CKS1B | P61024 | 1/20 | 0.41 |
| ▸ | SKP1 | P63208 | 1/20 | 0.41 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24485967 | 0.88 | GPR119 (0.49) | GPR119GLP1REGLN2PGGT1B | |
| SCHEMBL24320504 | 0.87 | GPR119 (0.49) | GPR119GLP1RMAP4K4CKS1BSKP1 | |
| SCHEMBL20266356 | 0.87 | GLP1R (0.53) | GPR119GLP1R | |
| SCHEMBL24485508 | 0.87 | GPR119 (0.54) | GPR119EGLN2PGGT1B | |
| SCHEMBL29826099 | 0.87 | GLP1R (0.53) | GPR119GLP1R | |
| SCHEMBL29668491 | 0.86 | GPR119 (0.49) | GPR119GLP1REGLN2PGGT1B | |
| SCHEMBL24485819 | 0.86 | GPR119 (0.49) | GPR119GLP1REGLN2PGGT1B | |
| SCHEMBL29668583 | 0.85 | GPR119 (0.47) | GPR119GLP1REGLN2PGGT1B | |
| SCHEMBL24485875 | 0.85 | GPR119 (0.47) | GPR119GLP1REGLN2PGGT1B | |
| SCHEMBL24455270 | 0.84 | GPR119 (0.57) | GPR119GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4247804-A1 | POLYHETEROCYCLIC GLP-1 R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-09-27 | — | — | EP | disclosed |
| WO-2022109182-A9 | POLYHETEROCYCLIC GLP-1 R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022109182-A9 | POLYHETEROCYCLIC GLP-1 R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-12-08 | — | — | WO | disclosed |
| US-20220177449-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2022-06-09 | — | — | US | disclosed |
| WO-2022109182-A1 | POLYHETEROCYCLIC GLP-1 R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
| WO-2022109182-A1 | POLYHETEROCYCLIC GLP-1 R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177449-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | GPR119 3/4885GLP1R 1/4885EGLN2 1823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.